由Informa Pharmaceutical Science出版(原Ashley Publications)。ISSN: 1354 - 3784。《研究藥物專家意見》(EOID)是一份經(jīng)同行評(píng)審的月刊，評(píng)估藥物研究的進(jìn)展，從動(dòng)物研究到新藥物的推出。鼓勵(lì)作者對(duì)審查中的研究現(xiàn)狀發(fā)表專家意見，而不是簡(jiǎn)單地審查現(xiàn)有數(shù)據(jù)。每期雜志還包括社論、藥物評(píng)價(jià)、臨床試驗(yàn)報(bào)告、會(huì)議紀(jì)要和論文評(píng)價(jià)。觀眾包括制藥行業(yè)的科學(xué)家、經(jīng)理和決策者，以及與研發(fā)密切相關(guān)的其他人。用戶包括美國(guó)、歐洲和日本的大多數(shù)主要制藥公司，以及許多生物技術(shù)公司。研究藥物的專家意見采用系統(tǒng)的方法進(jìn)行覆蓋，每個(gè)問題都集中在一個(gè)主要的治療領(lǐng)域。

Published by Informa Pharmaceutical Science (formerly Ashley Publications). ISSN: 1354-3784.Expert Opinion on Investigational Drugs (EOID) is a monthly peer-reviewed journal, evaluating developments in pharmaceutical research, from animal studies through to the launch of a new medicine. Authors are encouraged to express their Expert Opinion of the status of the research under review, rather than simply reviewing the available data. Each issue of the journal also contains Editorials, Drug Evaluations, Clinical Trial Reports, Meeting Highlights and Paper Evaluations. The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D. Subscribers include most of the major pharmaceutical companies in the USA, Europe and Japan, and many biotechnology companies. Expert Opinion on Investigational Drugs adopts a systematic approach to coverage, with each issue focusing on one of the major therapeutic areas.